Revised forecast
Fiscal year ending March 2027 · Full yearPrevious forecast published 15 May 2026The bar length represents the relative magnitude of change, based on the item that changed the most in this document. The percentage change shown by the dotted line is calculated from the two reported figures because the company did not provide the rate.
Following approval of the insurance reimbursement price for ReHeart, sales and cost of sales for ReHeart sales, the CDMO business and other operations were reflected in the forecast, resulting in expected improvements in profit at each stage. In addition, the expected amount of the regenerative medicine CDMO subsidy receipt was included as subsidy income in non-operating income, resulting in expected reductions in ordinary loss and net loss attributable to owners of the parent.
| Item | Details |
|---|---|
| Net Sales | Not disclosed → ¥540 million |
| Operating profit | ¥-1,430 million → ¥-1,030 million |
| Ordinary income | ¥-1,400 million → ¥-580 million |
| Profit attributable to owners of the parent | ¥-1,390 million → ¥-570 million |
| Net income per share | -168.33 yen and sen → -69.01 yen and sen |
| Fiscal Period Covered | Fiscal year ending March 2027 |
| Period Covered | Full year |
| Publication date of previous forecast | 15 May 2026 |
| Previous-period results | Sales: ¥212 million; operating loss: ¥1,081 million; ordinary loss: ¥1,028 million; net loss attributable to owners of the parent: ¥1,022 million; loss per share: ¥124.54 |
| Reason for the revision | Following approval of the insurance reimbursement price for ReHeart, sales and cost of sales for ReHeart sales, the CDMO business and other operations were reflected in the forecast, resulting in expected improvements in profit at each stage. In addition, the expected amount of the regenerative medicine CDMO subsidy receipt was included as subsidy income in non-operating income, resulting in expected reductions in ordinary loss and net loss attributable to owners of the parent. |
| Consolidated / non-consolidated | Consolidated |
Items this document does not state (2)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Following approval of the insurance reimbursement price for ReHeart, sales and cost of sales for ReHeart sales, the CDMO business and other operations were reflected in the consolidated earnings forecast, resulting in expected improvements in profit at each stage. In addition, the expected amount of the regenerative medicine CDMO subsidy receipt was included in non-operating income, resulting in expected reductions in ordinary loss and net loss attributable to owners of the parent.